Ludlow Capital Adds Sinovac to China Small Cap Index
Wednesday July 19, 11:39 am ET
BEIJING, July 19 /Xinhua-PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex:
SVA -
News), a leading provider of biopharmaceutical products in China, announced today that it has been added as a component of the Ludlow China SmallCap Index. Gerry Salazar, President of the Ludlow SmallCap China Index commented, "The launch of the Ludlow China SmallCap Index now gives both institutional and individual investors a gauge to track the overall performance of small cap Chinese equities."
Mr. Weidong Yin, Chief Executive Officer of Sinovac, remarked, "We are honored to be recognized by Ludlow Capital as one of the leading China-based small cap companies traded in the U.S."
In 2006, Sinovac will continue to focus its marketing efforts on domestic sales, particularly its inactivated hepatitis A vaccine, Healive. Sinovac is increasing the production and sales of Healive to capture a larger market share in anticipation of live attenuated hepatitis A vaccines exclusion in China by the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), effective January 1, 2006. Sinovac also expects to begin sales of its proprietary influenza vaccine, Anflu, in the product's first full flu sales season.
About Ludlow China SmallCap Index
The Ludlow Small Cap China Index is a basket of some of the top US traded OTC and small cap Chinese stocks. The Index provides institutional and individual investors a gauge for tracking the day-to-day performance of small cap Chinese stocks in a diversified basket. The index is designed for investors who have a long-term bullish outlook on China's emerging small cap market. The Ludlow China Index is owned and operated by Ludlow China Fund, Inc., based in New York City. For more information on the Ludlow China SmallCap Index and components visit
www.ludlowcapital.com/indices/
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
CONTACT:
Craig H. Bird
Segue Investor Relations
Phone: (215) 885 - 4981
Fax: (215) 885 - 4982
Contact: Ludlow China Index
Gerry Salazar
Tel.: +1-718-855-8451
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.
EN
